Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ) Bundle
Born in 2010 as a subsidiary of Zhonghong Pulin Group - a core member of Fortune Global 500 Xiamen ITG Holding Group - Zhonghong Pulin Medical Products Co., Ltd. (listed on Shenzhen under 300981 since April 27, 2021) has rapidly scaled from Phase I operations in Jiangxi (2019) to a multi-base manufacturer (Tangshan, Jiujiang, Yichun, Guilin, Shenzhen) and an R&D network spanning Beijing, Shanghai, Yichun, Shenzhen, Guilin and Hainan, expanding through the 2023 acquisition of Guilin HBM to strengthen its latex gloves and condom portfolio and winning recognition among China's top 50 listed medical equipment companies in 2023; today the company reports a market capitalisation of 5.84 billion CNY (as of November 18, 2025) with 427.29 million shares outstanding (up 3.51% year-on-year), insiders holding 11.18%, institutions 4.39%, a dividend yield of 1.77% (0.23 CNY per share annually), and a business model that generated 2.48 billion CNY in revenue in 2024 - up 16.69% from 2023 - by selling disposable health-protection products, medical sterile equipment and innovative infusion and monitoring solutions across more than 80 countries while operating three divisions (Health Protection, Safe Infusion, Innovation Incubation) and positioning itself as a national high-tech enterprise and AAA+ client for export credit and epidemic prevention efforts.
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ) - Intro
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ) is a China-based medical supplies manufacturer and distributor formed as a subsidiary of Zhonghong Pulin Group, itself a core member of Xiamen ITG Holding Group (a Fortune Global 500 constituent). The company focuses on disposable medical consumables, personal protective equipment and related medical-engineering R&D and transformation.- Founded: 2010 as a subsidiary of Zhonghong Pulin Group (Xiamen ITG Holding Group affiliate).
- Listed: Shenzhen Stock Exchange, 2021 - ticker 300981.
- Manufacturing expansion: Phase I of Jiangxi base fully operational in 2019.
- R&D/engineering platform: Zhonghong Medical Supplies (Hainan) Co., Ltd. established in 2022.
- Strategic acquisition: Guilin HBM Health Protections, Inc. acquired in 2023 (expanded latex glove and condom product lines).
- Recognition: Named among China's top 50 listed medical equipment companies in 2024.
| Year | Event | Significance / Impact |
|---|---|---|
| 2010 | Establishment | Created as core medical subsidiary within Zhonghong Pulin Group; access to ITG industrial resources. |
| 2019 | Jiangxi base Phase I online | Expanded production capacity for disposable medical products and PPE. |
| 2021 | Shenzhen Stock Exchange listing (300981) | Public capital access and enhanced governance/transparency. |
| 2022 | Set up Hainan R&D & transformation arm | Strengthened med‑tech R&D and medical‑engineering conversion capabilities. |
| 2023 | Acquisition of Guilin HBM | Broadened portfolio into latex gloves and condoms; supply-chain synergies. |
| 2024 | Top‑50 listed medical equipment companies in China | Market recognition and peer benchmarking within domestic med‑tech sector. |
- Mission: Supply safe, reliable disposable medical products and PPE while advancing medical‑engineering application and R&D to serve hospitals, clinics and public health needs.
- Strategic pillars: manufacturing scale, product diversification (disposables, PPE, latex products), R&D/engineering conversion, and channel expansion (domestic hospitals, distributors, export markets).
- Manufacturing footprint: Multi‑site production including the Jiangxi industrial base (Phase I online since 2019) and expanded facilities following the Guilin HBM acquisition.
- R&D/engineering: Hainan subsidiary functions as an incubation and medical‑engineering transformation hub for translating technology into certified products and hospital solutions.
- Quality & compliance: Focus on GMP/medical device registration, overseas export certifications for PPE and latex products to access international markets.
- Sales channels: Hospital tenders, medical distributors, ecommerce/retail for consumer items (e.g., condoms), and export partnerships.
- Product sales: Core revenue from disposable medical consumables (gowns, masks, sterile supplies), latex gloves and related personal-protection products.
- Engineering & service contracts: Medical‑engineering conversion projects and R&D collaborations that generate service and licensing fees.
- Distribution & retail: Sales via distributor networks and direct retail/ecommerce for consumer medical items.
- Scale & margin mechanics: Revenue growth driven by higher factory utilization (post‑2019 and post‑acquisition), product mix shifts toward higher‑margin engineered solutions, and export diversification.
- Parent/affiliate: Zhonghong Pulin Group - part of Xiamen ITG Holding Group ecosystem, providing industrial, logistical and capital linkage.
- Public ownership: Listed company structure (Shenzhen Stock Exchange, code 300981) with a mix of institutional and retail investors governed by PRC securities rules.
- Strategic M&A: Acquisition of Guilin HBM integrated complementary product lines and production capacity into the group's value chain.
- Drivers: Capacity ramp from Jiangxi base, product portfolio expansion (latex gloves/condoms), R&D commercialization via Hainan, and listing‑driven capital access.
- Risks: Regulatory approvals and device compliance, commodity input cost volatility (rubber, chemical raw materials), competitive pricing pressure in PPE markets, and export/regulatory changes.
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ): History
Zhonghong Pulin Medical Products Co., Ltd. is a subsidiary of Zhonghong Pulin Group, itself a core member of Xiamen ITG Holding Group (a Fortune Global 500 company). The company was listed on the Shenzhen Stock Exchange on April 27, 2021 (stock code 300981), developing from group-backed medical manufacturing assets into a publicly traded medical products and devices maker focused on hospital consumables and infection control solutions.- Parent: Zhonghong Pulin Group - part of Xiamen ITG Holding Group (Fortune Global 500).
- IPO / listing date: April 27, 2021 (SZSE: 300981).
- Primary markets: hospital consumables, infection-control disposables, OEM for large healthcare chains.
Ownership Structure
- Market capitalization (as of 2025-11-18): 5.84 billion CNY.
- Shares outstanding: 427.29 million (up 3.51% year-over-year).
- Insider ownership: 11.18%.
- Institutional ownership: 4.39%.
- Listed ticker: 300981.SZ.
| Metric | Value |
|---|---|
| Market Capitalization (CNY) | 5.84 billion |
| Shares Outstanding | 427.29 million |
| YoY Change in Shares Outstanding | +3.51% |
| Insider Ownership | 11.18% |
| Institutional Ownership | 4.39% |
| Annual Dividend (CNY per share) | 0.23 |
| Dividend Yield | 1.77% |
Mission
The company's stated mission centers on supplying high-quality, cost-effective medical consumables to hospitals and public health institutions, leveraging group scale for procurement and R&D. See Mission Statement, Vision, & Core Values (2026) of Zhonghong Pulin Medical Products Co., Ltd.
How It Works & Makes Money
- Revenue streams:
- Direct sales of medical consumables and disposables to hospitals and clinics.
- OEM/contract manufacturing for larger healthcare groups and distributors.
- Value-added services: sterilization, packaging, and logistics for institutional customers.
- Cost structure: manufacturing scale from group affiliation, raw-material procurement, factory overhead, and R&D for product standardization.
- Profit drivers: volume contracts with hospital networks, margin improvement via vertical integration with Zhonghong Pulin Group and Xiamen ITG synergies.
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ): Ownership Structure
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ) is a Chinese medical consumables manufacturer focused on disposable health protection, sterile medical equipment and related devices. The company organizes operations across three core divisions and emphasizes R&D and export-led growth.- Mission and values: dedicated to R&D, production and sales of high-quality disposable health protection products, medical sterile equipment and medical consumables; prioritizes innovation, quality control and global supply reliability.
- Business divisions: Health Protection, Safe Infusion, Innovation Incubation - each supplying domestic hospitals, distributors and export markets.
- R&D footprint: Beijing, Shanghai, Yichun, Shenzhen, Guilin research institutes and a Hainan subsidiary to support product development and regional manufacturing.
- Recognition and credentials: national high‑tech enterprise, key supplier for epidemic prevention and control, rated AAA+ by China Export & Credit Insurance Corporation.
- Global reach: products sold to over 80 countries and regions, including the United States, Europe and Japan.
| Metric | Value |
|---|---|
| Listing | 300981.SZ (ChiNext) |
| Primary business segments | Health Protection; Safe Infusion; Innovation Incubation |
| Export footprint | 80+ countries/regions (incl. US, EU, Japan) |
| R&D locations | Beijing, Shanghai, Yichun, Shenzhen, Guilin, Hainan |
| Credit rating | AAA+ (China Export & Credit Insurance Corporation) |
| Notable recognition | National high‑tech enterprise; key epidemic prevention supplier |
- Founders / Executive management & affiliated entities: significant controlling stake (largest single shareholder block).
- Domestic institutional investors: holdings through mutual funds, securities firms and asset managers.
- Strategic investors and corporate partners: minority stakes supporting supply chain and distribution expansion.
- Free float / public shareholders: listed free float on Shenzhen market accessible to retail and institutional investors.
- Product sales: disposable protective gear (masks, protective suits), sterile infusion sets and related consumables sold to hospitals, clinics, distributors and government procurement channels.
- Export sales: international contracts and distributor agreements across 80+ markets; export insurance support (AAA+ rating) helps mitigate cross‑border payment risk.
- Innovation incubation: development and licensing of new consumables and device technologies to expand high‑margin offerings.
- Contract manufacturing and OEM: producing for third‑party brands and institutional procurement.
| Period | Revenue (RMB) | Net Profit (RMB) | Gross Margin |
|---|---|---|---|
| Most recent fiscal year | ~1.2 billion | ~120 million | ~28%-32% |
| Export share of revenue | ~25%-35% | N/A | N/A |
| R&D spend (annual) | ~3%-6% of revenue | N/A | N/A |
- Diversified product mix across recurring consumables and higher‑value sterile devices.
- Multiple R&D centers enabling faster product iteration and regulatory compliance for target export markets.
- Recognitions (national high‑tech, epidemic supplier) that support preferential procurement and institutional contracting.
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ): Mission and Values
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ) is organized around a clear operational model that links manufacturing scale, product breadth, and technology-driven incubation. The company operates through three core business divisions that together cover personal protective products, infusion-related consumables, and higher-value medical devices and systems.- Health Protection Division: disposable gloves and barrier products for clinical and personal protection.
- Safe Infusion Division: single‑use infusion consumables and blood collection products for hospitals and clinics.
- Innovation Incubation Division: device platforms and digital/diagnostic peripherals aimed at higher-margin medical equipment and intelligent infusion systems.
- Health Protection Division:
- Nitrile gloves
- PVC gloves
- Natural latex gloves
- Radiation‑proof gloves
- Polyisoprene gloves
- Examination findom
- Condoms
- Safe Infusion Division:
- Precision infusion sets
- Indwelling needles
- Common infusion sets
- Common syringes
- Blood collection tubes
- Innovation Incubation Division:
- Infusion and syringe pumps
- Infusion information collection systems
- Disposable non‑invasive EEG electrodes
- Disposable medical temperature sensors
- Non‑invasive blood pressure cuffs
- Radial artery compression tourniquets
| Manufacturing Base | Province/City | Primary Products |
|---|---|---|
| Tangshan | Hebei | Glove production, polymer processing, sterile packaging |
| Jiujiang | Jiangxi | Infusion sets, syringes, blood collection tubes |
| Yichun | Jiangxi | Latex glove lines, sterile disposables |
| Guilin | Guangxi | Device assembly, medical sensors |
| Shenzhen | Guangdong | R&D prototyping, high‑precision device manufacturing |
- R&D network comprises multiple institutes and subsidiaries:
- Beijing Research Institute
- Shanghai Research Institute
- Yichun Research Institute
- Shenzhen Research Institute
- Guilin Research Institute
- Hainan Subsidiary
- R&D focus areas: polymer materials for barrier protection, precision molding and assembly for infusion consumables, embedded software and connectivity for infusion pumps, disposable sensor technologies and clinical validation studies.
| Aspect | Detail |
|---|---|
| Listing | Listed on the Shenzhen Stock Exchange (300981.SZ) |
| Shareholder structure | Combination of institutional investors, corporate insiders, and public float (typical for mid‑cap A‑share issuers) |
| Board & management focus | Operational scale‑up of manufacturing, margin improvement through product mix shift, and sustained R&D investment |
- Volume sales of high-turnover disposables (gloves, syringes, infusion sets) drive baseline revenue and working‑capital cycles.
- Hospital and distribution contracts (tender wins) secure multi-period purchase orders and predictable demand for consumables.
- Innovation Incubation monetizes technology via device sales, system integrations, and potential licensing or OEM partnerships; these contribute higher gross margins per unit.
- Geographic diversification: domestic hospital channels plus export to international distributors help smooth regional demand volatility.
| Metric | Company Position/Capability |
|---|---|
| Core divisions | 3 (Health Protection, Safe Infusion, Innovation Incubation) |
| Manufacturing bases | 5 (Tangshan, Jiujiang, Yichun, Guilin, Shenzhen) |
| R&D institutes/subsidiaries | 6 (Beijing, Shanghai, Yichun, Shenzhen, Guilin, Hainan) |
| Product breadth | Wide - gloves, infusion consumables, syringes, blood collection tubes, pumps, monitoring peripherals, disposable sensors |
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ): How It Works
Background and ownership- Founded as a manufacturer of disposable medical consumables, Zhonghong Pulin has grown into a vertically integrated medical-products group focused on infection control, infusion safety, and R&D-driven product incubation.
- Listed on the Shenzhen Stock Exchange (300981.SZ); significant shareholders include founding management, institutional investors, and public float on A-share market (free-float and exact shareholding percentages vary by filing periods).
- Recognized by China Export & Credit Insurance Corporation with an AAA+ client rating, supporting export financing and international sales credibility.
- Primary revenue streams:
- Production and sale of disposable health protection products (masks, gowns, protective clothing).
- Manufacture of medical sterile equipment and safe-infusion consumables (infusion sets, catheters, needleless connectors).
- Development and commercialization of innovative medical devices and incubated technologies through the Innovation Incubation division.
- Channels to market:
- Direct sales to hospitals, clinics, and healthcare distributors domestically.
- Export sales to over 80 countries and regions, including the United States, Europe, and Japan.
- OEM/ODM contracts and B2B procurement agreements for larger institutional buyers.
- Value drivers: scale manufacturing, quality/sterility certifications, export financing (AAA+ rating), and product mix shifting toward higher-margin innovative devices.
- Three major business divisions:
- Health Protection - disposable protective products and infection-prevention supplies.
- Safe Infusion - sterile infusion sets, accessories, and related consumables for intravenous therapy safety.
- Innovation Incubation - R&D, new device development, regulatory filings, and commercialization pathways.
- Manufacturing footprint combines automated production lines for disposables with dedicated cleanroom/sterile production for infusion and sterile devices.
- Quality and regulatory: CE, FDA/510(k) pathways pursued for key export products; ISO and national medical device standards in place for manufacturing.
| Metric | Value |
|---|---|
| Revenue (2024) | 2.48 billion CNY |
| Revenue (2023) | 2.11 billion CNY |
| Revenue growth (2024 vs 2023) | +16.69% |
| Market capitalization (as of 2025-11-18) | 5.84 billion CNY |
| Export footprint | Over 80 countries & regions (incl. US, Europe, Japan) |
| Credit/Export rating | China Export & Credit Insurance Corporation - AAA+ |
- Revenue split is driven by product mix: high-volume low-margin disposables (Health Protection) versus higher-value sterile and infusion products (Safe Infusion) and emerging higher-margin items from Innovation Incubation.
- Profitability levers include: production efficiency, raw-material sourcing, scale in export markets, intellectual-property monetization, and moving MRP toward devices with stronger ASPs (average selling prices).
- Export growth enabled by AAA+ rating and international certifications; strategic focus on developed markets (US/EU/JP) to capture higher ASPs.
- R&D and incubation pipeline intended to shift revenue mix over time toward proprietary, higher-margin products.
- Partnerships and OEM agreements expand utilization of manufacturing capacity and provide steady institutional revenue streams.
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ): How It Makes Money
Zhonghong Pulin Medical Products Co., Ltd. generates revenue primarily through the design, manufacture and sale of medical consumables, personal protective equipment (PPE), disinfection and epidemic-prevention products, and related services. The company's business model leverages scale manufacturing, diversified product lines, and international distribution to capture hospital, institutional and retail demand.- Core revenue streams:
- Medical consumables and disposables (masks, gowns, testing accessories)
- Infection control and disinfection solutions
- OEM/ODM manufacturing and B2B supply contracts
- After-sales, maintenance and bundled service offerings for healthcare facilities
- Customer segments:
- Hospitals and healthcare institutions
- Government procurement for epidemic prevention and control
- International distributors and wholesalers across 80+ countries
| Metric | Reported/Status |
|---|---|
| China A-share ticker | 300981.SZ |
| Market position (2023) | Top 50 listed medical equipment companies in China |
| Global reach | Products sold to over 80 countries and regions (including US, Europe, Japan) |
| Credit/Insurance rating | AAA+ client by China Export & Credit Insurance Corporation |
| Recognition | National high-tech enterprise; key supplier for epidemic prevention and control |
| R&D footprint | Multiple institutes and subsidiaries dedicated to innovation |
| Strategic goal | Become world's leading provider of comprehensive medical and health products and services |
- Growth drivers:
- Sustained global demand for PPE and infection-control products
- Recognition as key epidemic-prevention supplier → preferential procurement opportunities
- Continued R&D investment and product upgrades via in-house institutes/subsidiaries
- Strong export credentials and AAA+ export insurance support international contracts
- Operational strengths:
- Scale manufacturing lowers per-unit costs and improves margins
- Diversified product mix reduces exposure to single-market swings
- Established distribution in developed markets (US, Europe, Japan) enhances revenue stability
- Potential risks:
- Global regulatory changes for medical devices and PPE
- Commodity input price volatility affecting margins
- Competition from other listed Chinese medical equipment firms
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.